Method for detecting genetic disease

A hemagglutination reaction using fucose-specific lectins or antibodies in patient blood effectively detects SLC35C1 gene mutations, addressing the need for a simple diagnostic method for SLC35C1 deficiency by identifying the absence of fucose-containing sugar chains on red blood cells.

WO2024242050A1PCT designated stage expired Publication Date: 2024-11-28SOKA UNIVERSITY +2
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/018341
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-19
Filing Date
2024-05-17
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

There is a need for a simple and effective method to detect patients with SLC35C1 gene deficiency, which causes loss-of-function mutations leading to impaired glycosylation and associated genetic diseases, as current methods are not sufficiently straightforward or reliable.

Method used

A method involving a hemagglutination reaction using lectins or antibodies specific to fucose-containing sugar chains on red blood cells, such as UEA-I, AAL, AFL, and PhoSL, to determine the presence of loss-of-function mutations in the SLC35C1 gene by assessing the reaction's absence or insufficiency in patient blood compared to controls.

Benefits of technology

This method allows for the accurate detection of SLC35C1 gene mutations by identifying the absence of fucose-containing sugar chains on red blood cells, distinguishing between patients with Bombay blood type and those with SLC35C1 deficiency, thereby aiding in diagnosis and potential treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2024018341_28112024_PF_FP_ABST
    Figure JP2024018341_28112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention addresses the problem of providing a method capable of detecting or determining by a simple method a patient having a loss-of-function mutation in an SLC35C1 gene. The present invention provides a method for determining whether or not, in a subject, a loss-of-function mutation occurs in an SLC35C1 gene encoding a GDP-fucose transporter or determining whether or not the subject is suspected to have the loss-of-function mutation, the method including a step for performing a hemagglutination reaction using blood from the subject and using a lectin or antibody capable of recognizing an erythrocyte sugar chain antigen containing fucose.
Need to check novelty before this filing date? Find Prior Art

Description

Methods for detecting genetic diseases

[0001] The present invention relates to a method for detecting a patient with a loss-of-function mutation in the SLC35C1 gene, and more particularly to a method for determining whether a subject has said mutation by performing a hemagglutination reaction of the subject's blood using a lectin or antibody specific for fucose.

[0002] Glycosylation is carried out in the lumen of the endoplasmic reticulum and Golgi apparatus by various glycosyltransferases. Glycosyltransferases require high-energy donor sugars, which are activated by the addition of nucleoside monophosphates or diphosphates (CMP, UDP, or GDP), called sugar nucleotides. In the case of CMP-sialic acid, the sugar nucleotides are synthesized in the cytosol or nucleus. The movement of sugar nucleotides from the cytosol to the lumen of each compartment is mediated by sugar nucleotide transporters. Sugar nucleotide transporters transport sugar nucleotides by binding to the antiporter of the nucleoside monophosphate generated as a result of the glycosyltransferase reaction followed by the luminal nucleoside diphosphatase reaction. Therefore, sugar nucleotide transporters are considered to be important components in glycoconjugate synthesis.

[0003] The GDP-fucose transporter (encoded by the SLC35C1: Solute Carrier Family 35 Member C1 gene) is a member of the sugar nucleotide transporter family, a multi-spanning membrane protein present in the endoplasmic reticulum (ER) or Golgi membrane. SLC35C1 is a guanosine diphosphate-fucose (GDP-Fuc) transporter and a key regulator of glycan fucosylation. SLC35C1 transports GDP-Fuc from the cytosol to the lumen of the Golgi apparatus by binding to the GMP antiporter, providing the donor substrate GDP-Fuc to various fucosyltransferases. Two α1,2-fucosyltransferases, H-transferase (FUT1) and Secretor-transferase (FUT2), synthesize the sugar chain known as the H antigen of the ABO blood group by adding fucose to terminal galactose residues.

[0004] Patients with homozygous null SLC35C1 variants are predicted to exhibit the Bombay phenotype, characterized by a complete lack of A, B, and H (O) blood group carbohydrate antigens (Dipta T, Hossain A. 2011. The Bombay blood group: Are we out of risk? Mymensingh Med J. 20:536-540). SLC35C1 also provides GDP-Fuc to other fucosyltransferases, which are responsible for the addition of α1,6 core fucose (FUT8) and terminal α1,3 / 4 fucose (FUT3-7 and FUT9-11). FUT7 synthesizes the sialyl Lewis X structures that form E-, P-, and L-selectin on leukocytes. Fut7-deficient mice have been reported to exhibit a phenotype reminiscent of human leukocyte adhesion deficiency II syndrome (LADII), including increased blood leukocytosis, defective expression of blood leukocyte E- and P-selectin ligand activity, and impaired neutrophil trafficking during inflammation. Therefore, it is thought that deficiency of SLC35C1 causes a lack of GDP-Fuc, resulting in the loss of sialyl Lewis X structures and the induction of LADII.

[0005] Patients with a deficiency of the SLC35C1 gene (GDP-fucose transporter deficiency) are recognized as having a congenital disorder of glycosylation type IIc characterized by moderate to severe psychomotor retardation, growth retardation, mild dysmorphology including bone morphology, abnormal blood type (Bombay phenotype), and impaired neutrophil motility due to fucosylation deficiency. However, the details of the fucosylation deficiency in these patients and the relationship between fucosylation deficiency and symptoms remain unknown.

[0006] There is a strong demand for a method that can easily detect patients with a deficiency in the SLC35C1 gene.

[0007] Dipta T, Hossain A. 2011. The bombay blood group: Are we out of risk? Mymensingh Med J. 20:536-540.

[0008] An object of the present invention is to provide a method for easily detecting patients with a deficiency in the SLC35C1 gene.

[0009] The present inventors have discovered that carbohydrate antigens displayed on the surface of erythrocytes from patients with loss-of-function mutations in the SLC35C1 gene do not react with lectins specific for fucose, thereby completing the present invention. Furthermore, the present inventors have found that by combining these with lectins specific for fucose, it is possible to distinguish between erythrocytes from subjects with Bombay blood type who lack the H antigen (O antigen) and those from patients who also have loss-of-function mutations in the SLC35C1 gene.

[0010] The present invention includes the following: [1] A method for determining whether a subject has or is suspected of having a loss-of-function mutation in the SLC35C1 gene encoding a GDP-fucose transporter, comprising the step of performing a hemagglutination reaction (preferably a red blood cell agglutination reaction) using blood from the subject and a lectin or antibody that recognizes a sugar chain antigen on blood cells (red blood cells or white blood cells, preferably red blood cells) that contains fucose. [2] The lectin or antibody that recognizes a sugar chain containing fucose is selected from Ulex Europaeus Agglutinin I (UEA-I), Aleuria Aurantia Lectin (AAL), BC2LCN (AiLecS1) lectin, Aspergillus fumigatus lectin (AFL), Pholiota squarrosa Lectin (PhoSL), E-Selectin, P-Selectin, L-Selectin, DC-SIGN, Lens Culinaris Agglutinin (LCA), Aspergillus oryzae lectin (AOL), Lotus Tetragonolobus Lectin (LTA), and European eel lectin (Anguilla anguilla). The method of determining the fucose-containing glycan according to [1] above, wherein the lectin or antibody recognizing the fucose-containing glycan is a lectin or antibody selected from the group consisting of lectin (AAA), PA-IIL, and RS-Fuc lectin. [3] The method of determining the fucose-containing glycan according to [1] above, wherein the lectin or antibody recognizing the fucose-containing glycan is a lectin or antibody recognizing a core fucose-containing glycan. [4] The method of determining the fucose-containing glycan according to [3] above, wherein the lectin or antibody recognizing the core fucose-containing glycan is a lectin selected from the group consisting of LCA, AOL, AAL, AFL, and PhoSL. [5] The method of determining the fucose-containing glycan according to [2] above, wherein the lectin or antibody recognizing the fucose-containing glycan is a combination of a lectin or antibody recognizing a core fucose-containing glycan and a lectin or antibody recognizing (preferably, predominantly recognizing) a glycan containing fucose at the non-reducing end of the glycan.[6] The method of determining whether or not a lectin is present in a glycan containing at least one core fucose selected from the group consisting of AAL, AFL, PhoSL, LCA, and AOL, and whether or not a lectin is present in a glycan containing at least one non-reducing end fucose selected from AAL, AFL, E-selectin, P-selectin, L-selectin, UEA-I, BC2LCN (AiLecS1), PA-IIL, and RS-Fuc (preferably, preferentially recognizes such lectin). [7] The method of determining whether or not a lectin is present in a glycan containing at least one core fucose selected from the group consisting of AAL, AFL, PhoSL, LCA, and AOL, and whether or not a lectin is present in a glycan containing at least one non-reducing end fucose selected from ... RS-Fuc (preferably, preferentially recognizes such lectin). [8] The method according to [1] above, wherein the antibody recognizing a fucose-containing sugar chain is at least one antibody selected from the group consisting of an anti-H antibody, an anti-sialyl Lewis X antibody, an anti-sialyl Lewis A antibody, an anti-Lewis X antibody, an anti-Lewis Y antibody, an anti-Lewis A antibody, an anti-Lewis B antibody, and an anti-core fucose antibody. [9] The method according to any one of [1] to [8] above, wherein the loss-of-function mutation is a nonsense mutation or a missense mutation.

[10] The method according to any one of [1] to [9] above, wherein the blood derived from the subject is peripheral blood.

[11] The method according to any one of [1] to

[10] above, further comprising the following step: determining that the subject has a loss-of-function mutation in the SLC35C1 gene when no hemagglutination reaction is observed in the subject's blood or when the reaction is insufficient compared to a control.

[12] The method of determining whether a subject with a loss-of-function mutation in the SLC35C1 gene is a subject requiring treatment or observation.

[13] A method of determining whether a subject has or is suspected of having a loss-of-function mutation in the SLC35C1 gene encoding a GDP-fucose transporter, comprising the step of performing an ELISA assay using blood from the subject and an antibody that recognizes a sugar chain antigen on blood cells (red blood cells or white blood cells) containing fucose.

[14] The method of determining whether or not blood from the subject patient undergoes a hemagglutination reaction (preferably a red blood cell agglutination reaction) in response to a lectin or antibody that recognizes a sugar chain that is a sugar antigen on blood cells (red blood cells or white blood cells, preferably red blood cells) and that contains fucose.

[15] A method of obtaining information to be used for diagnosing whether or not a subject patient has or is suspected of having a loss-of-function mutation in the SLC35C1 gene that encodes a GDP-fucose transporter, the information being whether or not blood from the subject patient undergoes a hemagglutination reaction (preferably a red blood cell agglutination reaction) in response to a lectin or antibody that recognizes a sugar chain that is a sugar antigen on blood cells (red blood cells or white blood cells, preferably red blood cells) and that contains fucose.

[16] The lectin or antibody that recognizes a sugar chain containing fucose includes Ulex Europaeus Agglutinin I (UEA-I), Aleuria Aurantia Lectin (AAL), BC2LCN (AiLecS1) lectin, AFL (Aspergillus fumigatus lectin), Pholiota squarrosa Lectin (PhoSL), E-Selectin, P-Selectin, L-Selectin, DC-SIGN, Lens Culinaris Agglutinin (LCA), Aspergillus oryzae lectin (AOL), Lotus Tetragonolobus Lectin (LTA), and European eel lectin (Anguilla anguilla var. ...

[17] The method according to

[16] above, wherein the lectin or antibody that recognizes a sugar chain containing fucose is a lectin or antibody that recognizes a sugar chain containing core fucose.

[18] The method according to

[17] above, wherein the lectin or antibody recognizing the glycan containing core fucose is a lectin selected from the group consisting of LCA, AOL, AAL, AFL and PhoSL.

[19] The method according to

[16] above, wherein the lectin or antibody recognizing the glycan containing fucose is a combination of a lectin or antibody recognizing a glycan containing core fucose and a lectin or antibody recognizing (preferably predominantly recognizing) a glycan containing fucose at the non-reducing end of the glycan.

[20] The method according to

[19] above, wherein the combination is a combination of a lectin that recognizes at least one glycan containing core fucose selected from the group consisting of AAL, AFL, PhoSL, LCA, and AOL, and a lectin that recognizes (preferably predominantly recognizes) at least one glycan containing non-reducing end fucose selected from AAL, AFL, E-selectin, P-selectin, L-selectin, UEA-I, BC2LCN (AiLecS1), PA-IIL, and RS-Fuc.

[21] The method according to

[20] above, wherein the combination is a combination of any of AAL, AFL, PhoSL, LCA, and AOL with UAE-I.

[22] The method according to

[16] above, wherein the antibody recognizing a fucose-containing sugar chain is at least one antibody selected from the group consisting of an anti-H antibody, an anti-sialyl Lewis X antibody, an anti-sialyl Lewis A antibody, an anti-Lewis X antibody, an anti-Lewis Y antibody, an anti-Lewis A antibody, an anti-Lewis B antibody, and an anti-core fucose antibody.

[23] The method according to any one of

[16] to

[23] above, wherein the loss-of-function mutation is a nonsense mutation or a missense mutation.

[24] The method according to any one of

[16] to

[23] above, wherein the blood derived from the subject is peripheral blood.

[25] A method for obtaining information to be used for diagnosing whether a target patient has or is suspected of having a loss-of-function mutation in the SLC35C1 gene encoding a GDP-fucose transporter, wherein the information is the result of performing an ELISA assay on blood from the target patient using an antibody that recognizes a sugar chain antigen on blood cells (red blood cells or white blood cells) that contains fucose.

[26] The method according to

[25] above, wherein the antibody that recognizes a sugar chain containing fucose is at least one antibody selected from the group consisting of an anti-H antibody, an anti-sialyl Lewis X antibody, an anti-sialyl Lewis A antibody, an anti-Lewis X antibody, an anti-Lewis Y antibody, an anti-Lewis A antibody, an anti-Lewis B antibody, and an anti-core fucose antibody.

[0011] According to the method of the present invention, it is possible to determine whether or not a subject has a loss-of-function mutation in the SLC35C1 gene by a simple method using the subject's blood.

[0012] The figure shows a 3D structural model of full-length SLC35C1. The figure shows the results of MALDI-TOF-MS analysis of glycosphingolipid glycans and free oligosaccharides prepared from peripheral blood samples from the patient, his parents, and a healthy control (blood type O). B shows a comparison by area. The figure shows the results of MALDI-TOF-MS analysis of N-glycans prepared from peripheral blood samples from the patient, his parents, and a healthy control (blood type O). The figure shows the comprehensive glycan profiles of plasma samples from the patient, his parents, and a healthy control (blood type O). The figure shows the results of a hemagglutination assay. A shows the results using AAL as the lectin, B shows the results using UEA-I, and C shows the results using LCA. The figure shows the results of FACS analysis of red blood cells from each sample using lectin (A: AAL or B: UEA-I). N.C. indicates the negative control for each sample and the control without the addition of lectin. The figure shows the results of FACS analysis of granulocytes (A), monocytes (B), and lymphocytes (C) from each sample using lectin (AAL or UEA-I). The samples used are indicated as patient (patient with SLC35C1 mutation), mother, father, and control. N.C. indicates the negative control for each sample and the control without the addition of lectin. The figure shows the results of FACS analysis of monocytes from each sample using P-secretin. The samples used are indicated as patient (patient with SLC35C1 mutation), mother, father, and control. N.C. indicates the negative control for each sample and the control without the addition of P-secretin. The figure shows the results of FACS analysis of EBV-transformed B cells established from a patient (with an SLC35C1 mutation), mother, and father. N.C. indicates the negative control for each sample, a control without antibody addition. Mean fluorescence intensity (MFI) represents the mean ± SEM of three independent experiments. Statistical significance is indicated by * (p<0.01) and ** (p<0.001).The figure shows the results of FACS analysis of EBV-transformed B cells derived from a patient (patient with SLC35C1 mutation) and a control (control: B cells) using lectins (A: AAL, B: LCA) and antibodies (C: anti-CSLEX antibody). N.C. indicates a negative control, a control to which no lectin or antibody was added. The left figure shows histograms of each stained sample, and the right figure shows the relative MFI normalized to each MFI of N.C. Statistical significance is indicated by * (p<0.01) or ** (p<0.001). ns indicates no significant difference. The figure shows the results of MALDI-TOF-MS analysis of N-glycans prepared from EBV-transformed B cells derived from a patient (patient with SLC35C1 mutation) and a control (control: B cells). A: B cells cultured under normal conditions; B: B cells cultured under fucose-supplemented conditions; C: patient-derived B cells cultured under normal conditions; D: patient-derived B cells cultured under fucose-supplemented conditions; E: culture medium.

[0013] The present invention will be described below, taking exemplary embodiments as examples, along with preferred methods and materials that can be used in carrying out the present invention, but the present invention is not limited to the embodiments described below. Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which the present invention belongs. Furthermore, any materials and methods equivalent or similar to those described herein can also be used in carrying out the present invention. Furthermore, all publications and patents cited in this specification in connection with the present invention are incorporated herein by reference and constitute a part of this specification, for example, to describe methods, materials, and the like that can be used in the present invention.

[0014] In the present invention, a "loss-of-function mutation in the SLC35C1 gene" refers to a mutation in the SLC35C1 gene encoding a GDP-fucose transporter, which results in some kind of defect in the GDP-fucose transporter, the product of the SLC35C1 gene, resulting in loss of function of the protein. Examples of such mutations include, but are not limited to, missense mutations, nonsense mutations, deletions, insertions, splice mutations, and combinations thereof, and particularly missense mutations.

[0015] Herein, "SLC35C1 mutation" and "SLC35C1 variant" are used as interchangeable terms. Herein, "recognizing" a glycan and "binding to" a glycan are used as interchangeable terms. Herein, "fucose at the non-reducing end of a glycan" and "terminal fucose" are used as interchangeable terms.

[0016] The subject of the present invention is a mammal, particularly a human. The blood derived from the subject of the present invention is not particularly limited, but is preferably peripheral blood. The blood used in the present invention is not particularly limited, and may be serum, plasma, or whole blood. Alternatively, blood cells (red blood cells or white blood cells) separated from such blood, more preferably red blood cells, may be used.

[0017] Erythrocyte carbohydrate antigens refer to carbohydrates expressed on the surface of erythrocytes. Examples include A / B / H carbohydrate antigens and Lewis carbohydrate antigens. Fucose present in carbohydrate antigens exists in various linkages. Blood group antigens of the Lewis blood group and ABO blood group are synthesized by linking sugars (Gal, GlcNAc, GalNAc, Fuc, NeuAc) to Galβ1→3GlcNAc using glycosyltransferases (Le enzyme, Se enzyme, ST enzyme, A enzyme, B enzyme). For example, fucose is linked 1→2 to the galactose of Galβ1→3GlcNAc using Se enzyme (FUT2 enzyme), forming H antigen (O antigen: Fucα1→2Galβ1→3GlcNAc). The Le enzyme (FUT3) attaches one fucose to N-acetylglucosamine (GlcNAc) via an α1→4 bond. FUT3 (Le enzyme) also has the activity of forming an α1→3 bond, resulting in the formation of both α1,3-Fuc and α1,4-Fuc bonds. This is called fucosylation (Lewis-type glycan antigen, H-type glycan antigen), in which fucose is attached to the non-reducing end of a glycoprotein (fucosylation) by fucose. As used herein, "fucose at the non-reducing end of a glycan" includes α1,2-Fuc, α1,3-Fuc, α1,4-Fuc, or a combination thereof.

[0018] In addition to the above, there is fucosylation (core fucose) attached to the reducing end of glycoproteins. Core fucose is fucose attached via an α1→6 bond to N-acetylglucosamine present at the reducing end (base) of N-glycans. Core fucose is synthesized by α1-6 fucosyltransferase (Fut8).

[0019] The lectin or antibody used in the present invention is a lectin or antibody that recognizes a sugar chain antigen on blood cells (red blood cells or white blood cells) and that recognizes a sugar chain containing fucose. In this specification, it is referred to as a "lectin or antibody that recognizes a sugar chain containing fucose." Lectins that can be used in the present invention are lectins that bind to sugar chain antigens on blood cells, which are sugar chains containing fucose, and include, but are not limited to, Ulex Europaeus Agglutinin I (UEA-I), Aleuria Aurantia Lectin (AAL), BC2LCN (AiLecS1) lectin, Aspergillus fumigatus lectin (AFL), Pholiota squarrosa Lectin (PhoSL), E-Selectin, P-Selectin, L-Selectin, DC-SIGN, Lens Culinaris Agglutinin (LCA), Aspergillus oryzae lectin (AOL), Lotus Tetragonolobus lectin (Lotus Tetragonolobus Examples of lectin include European eel lectin (Anguilla anguilla lectin: LTA), European eel lectin (Anguilla anguilla lectin: AAA), PA-IIL, and RS-Fuc lectin. BC2LCN (AiLecS1) lectin contains H type-1: SSEA-5, H type-3, and H type-4: Globo H glycolipids.

[0020] In one embodiment of the present invention, the lectin or antibody is a glycan antigen that can bind to glycans containing non-reducing terminal fucose (including Lewis-type fucose and H-type fucose) and glycans containing core fucose. For example, it is a lectin or antibody that binds to glycans containing α1,2-Fuc and α1,3-Fuc and also binds to glycans containing α1,6-Fuc. Here, the strength of binding to glycans containing α1,2-Fuc and α1,3-Fuc and the strength of binding to glycans containing α1,6-Fuc may be equal or stronger than each other. Examples of such lectins include, but are not limited to, AAL, AFL, and PhoSL. Alternatively, commercially available lectins with such binding specificities can be used in the present invention. Antibodies capable of binding to sugar chains containing terminal fucose, such as α1,2-Fuc and α1,3-Fuc, and antibodies capable of binding to sugar chains containing core fucose, can be obtained by standard methods using sugar chain antigens containing such fucose. Alternatively, commercially available antibodies with such binding specificity can be used in the present invention.

[0021] In another aspect of the present invention, the lectin or antibody is a lectin or antibody that recognizes glycans containing terminal fucose, such as α1,2-Fuc or α1,3-Fuc, and is preferably a lectin or antibody that preferentially recognizes glycans containing terminal fucose. A lectin or antibody that preferentially recognizes glycans containing terminal fucose refers to a lectin or antibody that binds to glycans containing terminal fucose but does not substantially bind to glycans containing core fucose, or whose binding strength to glycans containing core fucose is significantly weaker than its binding strength to glycans containing terminal fucose. For example, it refers to a lectin or antibody whose binding strength to glycans containing terminal fucose is at least two times, preferably three times, and more preferably five times, its binding strength to glycans containing core fucose. For example, the lectin or antibody may be a lectin or antibody whose binding strength to glycans containing α1,2-Fuc or α1,3-Fuc is stronger than its binding strength to glycans containing α1,6-Fuc. Examples of such lectins include, but are not limited to, UEA-I, E-selectin, P-selectin, L-selectin, DC-SIGN, PA-IIL, and RS-FUc. Alternatively, commercially available lectins with such binding specificity can be used in the present invention. Antibodies that preferentially recognize glycans containing terminal fucose can be obtained by conventional screening using glycan antigens with terminal fucose and further confirming cross-reactivity. Alternatively, commercially available antibodies with such binding specificity can be used in the present invention.

[0022] In another aspect of the present invention, the lectin or antibody is a lectin or antibody that recognizes glycans containing core fucose, or a lectin or antibody that preferentially recognizes glycans containing core fucose. A lectin or antibody that preferentially recognizes glycans containing core fucose refers to a lectin or antibody that binds to glycans containing core fucose but does not substantially bind to glycans containing terminal fucose, or whose binding strength to glycans containing terminal fucose is significantly weaker than its binding strength to core fucose. For example, it refers to a lectin or antibody whose binding strength to glycans containing core fucose is at least two times, preferably three times, and more preferably five times, its binding strength to glycans containing terminal fucose. Examples of such lectins include lectins or antibodies that have stronger binding strength to glycans containing α1,6-fucose than to glycans containing α1,2-fucose or α1,3-fucose. Examples of such lectins include, but are not limited to, LCA, AAL, AOL, AFL, and PhoSL. Alternatively, commercially available lectins with such binding specificity can be used in the present invention. Antibodies that preferentially recognize glycans containing core fucose can be obtained by conventional screening methods using glycan antigens with core fucose (α1,6-Fuc) and further confirming cross-reactivity. Alternatively, commercially available antibodies with such binding specificity can be used in the present invention. In this specification, antibodies that bind to glycans containing core fucose are referred to as "anti-core fucose antibodies."

[0023] In the determination method of the present invention, a hemagglutination reaction, e.g., a red blood cell agglutination reaction, is carried out using a lectin or antibody that recognizes a sugar chain antigen on red blood cells, preferably red blood cells, containing fucose. The hemagglutination reaction can be carried out according to standard methods. For example, it can be carried out as follows: A target sample, preferably plasma, is prepared and heated. A serial dilution series of the sample is prepared using a buffer solution such as PBS, and an appropriate concentration of the lectin or antibody is added and mixed thereto. The mixture is then left to stand, for example, at room temperature, 37°C, or a low temperature, for one to several hours. The presence or absence of agglutination is then confirmed. The agglutination test can be carried out using, for example, a 48-well or 96-well well plate, but is not limited thereto. If red blood cells react with the lectin or antibody and agglutinate, a uniform red solution is obtained. The red blood cell agglutination reaction is a very simple method and can be easily carried out without requiring special measuring equipment.

[0024] Lectins that can be used in the determination method of the present invention include (1) lectins or antibodies that bind to both glycans containing terminal fucose and glycans containing core fucose, (2) lectins or antibodies that bind predominantly to glycans containing terminal fucose, and (3) lectins or antibodies that bind predominantly to glycans containing core fucose. Herein, (1) lectins or antibodies that bind to both glycans containing terminal fucose and glycans containing core fucose, and (3) lectins or antibodies that bind predominantly to glycans containing core fucose, are collectively referred to as lectins or antibodies that bind to glycans containing core fucose. Neither terminal nor core fucose is present in the glycan antigens of blood cells, preferably red blood cells, derived from subjects with a loss-of-function mutation in the SLC35C1 gene, and therefore detection is possible using any of the lectins or antibodies described above in (1) to (3).

[0025] However, subjects lacking terminal fucose in the erythrocyte glycan antigen may also be considered. Examples of such subjects include those with the Bombay blood type. Therefore, in one embodiment of the present invention, a lectin or antibody that binds to glycans containing core fucose is used. In Bombay blood type individuals with glycans containing core fucose, such lectins or antibodies cause erythrocyte agglutination. Use of such antibodies can avoid the risk of false positives in the diagnosis. Therefore, in the present invention, a lectin or antibody that binds to glycans containing core fucose is preferably used. Furthermore, in one embodiment of the present invention, two lectins or antibodies can be used in combination. Examples include a combination of (1) a lectin or antibody that binds to both glycans containing terminal fucose and glycans containing core fucose and (3) a lectin or antibody that binds preferentially to glycans containing core fucose, or a combination of (2) a lectin or antibody that binds preferentially to glycans containing terminal fucose and (3) a lectin or antibody that binds preferentially to glycans containing core fucose. By using such a combination, subjects lacking core fucose-containing sugar chains in the sugar chain antigens of blood cells, preferably red blood cells, can be more accurately identified. In red blood cells derived from subjects with a loss-of-function mutation in the SLC35C1 gene, which is the subject of the present invention, no blood cell agglutination occurs with any of the combinations. However, in the Bombay type, which lacks terminal fucose, agglutination does not occur with the lectin or antibody (2), while agglutination does occur with the lectin or antibody (1) or (3), and agglutination is particularly easier to detect with the lectin or antibody (3). Thus, one aspect of the present invention is a determination method using a lectin or antibody that preferentially recognizes (binds to) sugar chains containing core fucose.

[0026] In one embodiment of the present invention, the lectin used is preferably LCA, AOL, AAL, AFL, or PhoSL, particularly preferably LCA. In another embodiment of the present invention, the lectin used is preferably a combination of UAE-I and any of LCA, AOL, AAL, AFL, or PhoSL, more preferably a combination of UAE-I and any of LCA, ALL, AFL, or PhoSL, and even more preferably a combination of UAE-I and LCA or a combination of UAE-I and AAL.

[0027] The determination method of the present invention can determine whether a loss-of-function mutation in the SLC35C1 gene is present or suspected, and can therefore also be used as an aid in diagnosis. If the determination method of the present invention results in a positive result, a definitive diagnosis can be made by combining it with another diagnostic method. Other diagnostic methods include, but are not limited to, genome analysis, MS analysis, etc.

[0028] The present invention will be described in detail below using examples, but the present invention is not limited to these examples. (Example 1) SLC35C1 Deficient Patient The following experiment was conducted with written informed consent for genetic testing from the patient and her family, and approval from the National Center for Child Health and Development. The patient was a female infant born by emergency cesarean section due to umbilical cord blood flow obstruction. Both parents had type B ABO blood types. The girl was born prematurely and admitted to the NICU as a low-birthweight infant. She was diagnosed with osteopenia of prematurity and developed bilateral conductive hearing loss due to severe otitis media with effusion at one month of age. She was discharged from the NICU at 73 days of age. The girl was followed for SGA dwarfism, and her short stature gradually became more pronounced. She was unable to walk at 2 years and 4 months of age. Her speech was limited to babbling, with no significant words. Direct sequencing of the FGFR3 gene did not reveal any pathogenic variants.

[0029] Example 2: Whole-exome sequencing and bioinformatics. Genomic DNA was extracted from whole blood cells using the QIAamp DNA Blood Mini Kit (QIAGEN, Germany), and whole-exome sequencing was performed. After filtering variants between patients and non-patients, a homozygous variant in the SLC35C1 gene was identified in the patient. No homozygous variant in the SLC35C1 gene was found in gnomAD. The variant was confirmed by Sanger sequencing. Co-segregation between the homozygous variant and the patient was confirmed in the family, suggesting it was the causative mutation.

[0030] (Example 3) Estimation of Loss of Activity in Variants The effect of the deletion on transporter activity was estimated as follows. An AlphaFold 3D structural model of the full-length SLC35C1 (Met1 to Val364) was created. The model is shown in Figure 1. The variant retains only the N-terminal region (Met1 to Pro66) of wild-type SLC35C1. This N-terminal portion corresponds to a short cytoplasmic helix and one transmembrane helix. As shown in the figure, the transporter activity of wild-type SLC35C1 is thought to be achieved by properly organized multiple transmembrane helices. However, the variant is unable to organize such an organization, and it was predicted that the variant would almost completely lack transporter activity.

[0031] Example 4 Analysis of Glycosylation Profiles Plasma was collected from the peripheral blood (peripheral blood supplemented with EDTA-2Na) of the patient and his parents and analyzed. The collected plasma was stored at -30°C until analysis. Samples for analysis were prepared from the plasma using the ethanol precipitation method as follows: 4 volumes of cold ethanol were added to 40 μL of plasma and allowed to stand at -30°C for 3 hours. The mixture was then centrifuged (14,000 x g) at 4°C for 20 minutes to separate the supernatant containing lipids from the residue containing proteins. 100 μL of ethanol was added to the residue, and the supernatant and residue were separated by centrifugation. The residue containing proteins was dissolved in 80 μL of distilled water and used for N-glycan analysis. Separately, for analysis of glycosphingolipid (GSL) glycans and free oligosaccharides (fOS), the supernatants were combined and completely dried in a centrifugal evaporator.

[0032] Preparation of N-glycans: A solution (equivalent to 4 μL of human plasma) containing protein residues was dissolved in water and dissolved in 100 mM aqueous ammonium bicarbonate containing 0.1% Triton X-100. 500 mM TCEP and 100 mM 2-iodoacetamide were added, and the mixture was subjected to reductive alkylation at room temperature in the dark. The denatured protein was digested with trypsin, and the reaction mixture was heated at 90°C for 15 minutes to inactivate the trypsin. 2 U of peptide N-glycanase was added, and the mixture was incubated at 37°C for 16 hours to perform deglycosylation, preparing N-glycans.

[0033] Preparation of glycosphingolipid sugar chains and free oligosaccharides. The concentrated, dried supernatant containing lipids was dissolved in 92 μL of acetate buffer (241 mM, pH 5.6) containing 0.16% Triton X-100, and 8 μL of 1.1 U / mL glucose oxidase was added to convert it to gluconolactone. EGCase I was then added and the mixture was incubated at 37°C for 16 hours to prepare glycosphingolipid sugar chains. The sample excluding the EGCase I enzyme treatment was used for free oligosaccharide analysis.

[0034] Glycoblotting and Aminolysis-SALSA Glycan Purification The N-glycans, glycosphingolipid glycans, and free oligosaccharides prepared above were purified by glycoblotting and aminolysis-SALSA. Internal standard glycans (A2GN1 (200 pmol) for N-glycans, and Maltopentaose (50 pmol) for glycosphingolipid glycans and free oligosaccharides) were added to 25-50 μl of each prepared glycan sample, and the glycans were chemoselectively immobilized on BlotGlyco® beads. Unreacted hydrazide groups on the beads were inactivated by acetylation, followed by washing, and then linkage-specific amide derivatization of sialic acids using the SialoCapper-ID Kit. Finally, the derivatized sugar chain was released from the solid support and simultaneously labeled at the reducing end with the aoWR reagent, and the labeled sugar chain was purified by removing excess aoWR reagent using a MassPrep HILIC μElution plate.

[0035] Purified, derivatized N-glycans, glycosphingolipid glycans, or free oligosaccharides were mixed with 2,5-dihydrobenzoic acid solution (10 mg / mL, prepared in 30% acetonitrile) and subjected to MALDI-TOF-MS analysis. All measurements were performed on an Ultraflex II TOF / TOF-MS instrument equipped with a reflector and controlled by FlexControl 3.0 software. All spectra were acquired in positive ion mode in reflectron mode with an accelerating voltage of 25 kV, a reflector voltage of 26.3 kV, and a pulsed ion extraction time of 170 ns. Absolute quantification was performed by comparing the area of ​​the MS signal for each glycan with known amounts of internal standards (A2GN1 and Maltopentaose).

[0036] As described above, glycosyl changes caused by SLC35C1 mutations were investigated using human plasma. The results are shown in Figure 2. We have reported that the expression levels of blood group-specific glycosphingolipid glycans and free oligosaccharides vary depending on ABO blood group and secretor status. Analysis of glycosphingolipid glycans revealed that mono- and difucosylated glycans (GSL-19 and -10), precursors of ABO blood group-specific glycans, were observed in all subjects. Analysis of glycosphingolipid glycans in healthy controls revealed fucosylated glycosphingolipid glycans (GSL-19 and -10) at m / z 1283.6 and 1429.7, respectively. Furthermore, type B-specific glycosphingolipid glycans (GSL-31 and -11) were also observed in the plasma of both parents at m / z 1445.5 and 1591.6. However, these glycosphingolipid glycans (GSL-19, GSL-20, and GSL-11) were not observed in the plasma of patients with SLC35C1 mutations. Fucα1-2Galβ1-4(Fucα1-3 / 4)Glc (fOS-7:LDFT) and α-galactosylated LDFT (fOS-8) strongly correlated with the expression of blood group-specific glycosphingolipid glycans (GSL-10 and 11) and were detected in the plasma of healthy controls and both parents, whereas type O-specific fOS-7 and parental (type B)-specific fOS-7 were not detected in patients.

[0037] The results of N-glycan analysis are shown in Figure 3. In N-glycan analysis, neutral glycans containing core fucose were detected in the plasma of healthy controls and parents. On the other hand, in SLC35C1 mutation patients, significant changes in plasma N-glycans lacking α1,6 fucose residues were observed. N-glycans containing fucose (N-16, N-21, N-25, N-46, N-57, N-61, N-66) were not detected in SLC35C1 mutation patients. N-16: (HexNAc)2(Fuc)1 + (Man)3(GlcNAc)2 N-21: (Hex)1(HexNAc)2(Fuc)1 + (Man)3(GlcNAc)2 N-25: (Hex)2(HexNAc)2(Fuc)1 + (Man)3(GlcNAc)2 N-46: (Hex)2(HexNAc)2(Fuc)1(NeuAc)1[α2,6] + (Man)3(GlcNAc)2 N-57: (Hex)2(HexNAc)2(Fuc)1(NeuAc)2[α2,6 / α2,6] + (Man)3(GlcNAc)2 N-61: (Hex)2(HexNAc)3(Fuc)1(NeuAc)2[α2,6 / α2,6] + (Man)3(GlcNAc)2 N-66: (Hex)3(HexNAc)3(Fuc)1(NeuAc)3[α2,3 / α2,6 / α2,6] + (Man)3(GlcNAc)2. For example, signals for sialylated and fucosylated A2F(N-57) and A3F(N-66) were barely detectable. The relative amount of fucosylated N-glycans was reduced to 0.12% in the plasma of SLC35C1-mutated patients compared with controls. These results suggest that SLC35C1 mutations lead to reduced GDP-fucose levels and, subsequently, to the absence of fucosylation of various glycoconjugate glycans in human plasma.

[0038] Figure 4 shows the comprehensive glycan profile of each subject's plasma. The pie charts at each vertex of the pentagon show the glycan expression profiles of N-glycans, free oligosaccharides (fOS), GAGs, GSL glycans, and O-glycans, with the area of ​​the circle representing the expression level. The estimated glycan composition, corresponding number, and expression level for all samples are summarized in Table 1 below. The boxed area represents fucosylated glycans, which accounted for approximately 30% of the N-glycans in the control and parental samples, while it was approximately 0.1% in the patient. Furthermore, no fucosylated glycans were detected in the patient's GSL glycans. The calculated proportion of fucosylated glycans in all glycans was approximately 25% in the control and parental samples, while it was less than 0.1% in the patient.

[0039]

[0040]

[0041] (Example 5) Confirmation of fucose expression on erythrocytes and leukocytes To confirm the expression of fucose on erythrocytes and leukocytes of patients with SLC35C1 mutations, hemagglutination assay and FACS analysis were performed using two types of lectins that recognize sugar chain structures containing fucose as follows.

[0042] Isolation of White Blood Cells and Red Blood Cells. Blood samples were collected from the SLC35C1 mutation patient (blood type O), the patient's father (blood type B), the patient's mother (blood type B), and a healthy control individual (blood type O) in tubes containing EDTA-2Na to prevent coagulation. White blood cells and red blood cells were separated using Lymphoprep (Abbott Diagnostics Technologies AS, Norway) according to the manufacturer's protocol. Briefly, blood was centrifuged at 3000 rpm for 20 minutes at 20°C, and the plasma (upper layer) was removed from the blood cell layer. The blood cells were diluted two-fold with PBS, and then 3 ml of Lymphoprep solution was added to the bottom of a 15 mL tube, and 6 ml of the blood cell suspension was carefully layered on top. The layered blood cells were centrifuged at 800 xg for 30 minutes at 20°C to collect white blood cells (buffy coat) and red blood cells (bottom layer), which were washed with PBS and used for analysis.

[0043] Hemagglutination Assay Using Lectins AAL and UEA-I were used as lectins and the assay was performed as follows. AAL recognizes fucose, and the binding strength to fucose is in the order of Fucα1-6 >> Fucα1-3 > Fucα1-4 > Fucα1-2. UEA-I preferentially recognizes Fucα1-2(1-2). LCA preferentially recognizes Fucα(1-6)GlcNAc (core fucosylated biantennary N-glycan). AAL and LCA recognize core fucose (α1-6 fucose) located at the base of N-glycans, whereas UEA-I recognizes Lewis fucose (α1-2 fucose) located at the terminal of N-glycans. Biotinylated Aleuria Aurantia Lectin (AAL) (VECTOR Laboratories; B-1395), biotinylated Ulex Europaeus Agglutinin I (UEA-I) (VECTOR Laboratories; B-1065), or biotinylated Lens Culinaris Agglutinin (LCA) (VECTOR Laboratories; B-1045) were serially diluted 5-fold in PBS (25 μg / ml, 5 μg / ml, and 1 μg / ml) and added to a 96-well V-bottom plate. 1 × 10 7The red blood cells were added to the solution and allowed to stand at 4°C for 1 hour. A homogeneous red solution was observed after red blood cell agglutination. The results of the hemagglutination assay are shown in Figures 5A-C. When red blood cells from a healthy control, mother, and father were added, agglutination was observed with all lectins, including AAL, UEA-I, and LCA. However, red blood cells from the SLC35C1 mutant patient did not agglutinate at any lectin concentration. This demonstrated that the patient's red blood cells do not express fucose-containing glycans. Furthermore, red blood cells from the SLC35C1 mutant patient did not agglutinate with either a lectin recognizing core fucose (α1-6 fucose) or a lectin recognizing H-type fucose (α1-2 fucose), demonstrating that both types of lectins can detect SLC35C1 mutant patients. The Bombay type lacks the activity of the enzyme (H enzyme) that transfers fucose at α1,2, resulting in a lack of H antigen. Therefore, it is thought that red blood cells derived from the Bombay type do not undergo agglutination reaction when a lectin recognizing Fucα1-2 is used. In such cases, by using a lectin recognizing Fucα1-6 (or, in some cases, by using a lectin recognizing Fucα1-6 in combination with a lectin recognizing Fucα1-2), it is possible to distinguish between the Bombay type, which is thought to be far more common than the SLC35C1 mutation, and the red blood cells of patients with the SLC35C1 mutation, thereby avoiding the risk of false positives.

[0044] FACS analysis 3-5×10 5Erythrocytes were suspended and washed with FACS buffer (PBS, 0.5% BSA). After washing, the cell suspension was incubated with the following lectins for staining: FITC-conjugated AAL (5 μg / ml), FITC-conjugated UEA-I (5 μg / ml), and FITC-conjugated LCA (25 μg / ml). After staining, the cells were fixed with PBS containing 0.4% paraformaldehyde. The samples were then analyzed using a BD FACSAria III Cell Sorter (Becton Dickinson). The results of FACS analysis of fucose expression on the cell surface of erythrocytes using AAL, UEA-I, and LCA are shown in Figure 6. FACS analysis indicated that erythrocytes from SLC35C1 mutation patients did not express fucose-containing glycans. This result was consistent with the results of the hemagglutination assay. This confirmed that fucose is hardly expressed on the surface of erythrocytes from SLC35C1-deficient patients. These results demonstrate that patients with SLC35C1 deficiency can be detected by a simple method known as hemagglutination using a substance (e.g., lectin or antibody) that recognizes fucose bonds in N-glycans on the surface of erythrocytes.

[0045] Similarly, the expression of fucose on the cell surface of leukocytes was examined by FACS analysis. Leukocytes are divided into three cell populations: granulocytes, monocytes, and lymphocytes. Leukocytes were stained with AAL, UEA-I, and LCA lectins, and analyzed by flow cytometry, gating on granulocytes, monocytes, and lymphocytes based on forward scatter signal (FSC) and side scatter signal (SSC). The results are shown in Figure 7. As a result, binding of AAL, UEA-I, and LCA lectins to the patient's cells was reduced compared to controls, the mother's, and the father's for all granulocytes, monocytes, and lymphocytes. Decreased expression of fucose-containing glycans was also confirmed in leukocytes from patients with SLC35C1 deficiency.

[0046] Example 6: P-Secretin Binding to Monocytes When inflammation occurs, leukocytes gather at the site of inflammation and infiltrate outside the blood vessels. Before infiltration, leukocytes undergo a stage called rolling, where they are captured by vascular endothelial cells. Rolling requires the interaction of selectins with ligand molecules on leukocytes and endothelial cells. However, leukocytes from patients with fucose deficiency are unable to adhere to vascular endothelium. Furthermore, Fut7-deficient mice exhibit impaired leukocyte adhesion. This adhesion defect due to fucose deficiency has been shown to be due to poor recognition of P-selectin on endothelial cells for P-selectin glycoprotein ligand-1 (PSGL-1) on leukocytes. Monocytes are attracted to inflammatory sites, differentiate into macrophages and dendritic cells, and produce proinflammatory cytokines. PSGL1 is expressed on monocytes and is required for P-selectin-mediated adhesion to endothelial cells. Therefore, we investigated whether P-selectin binding to monocytes from SLC35C1 mutant patients with reduced fucose expression was impaired. Recombinant human P-selectin Fc chimera (R&D Systems; 137-PS-050; 10 μg / ml) was added to the FACS buffer. For P-selectin reactions, 1 mM CaCl 2 was added to the FACS buffer. The cells were then incubated with FITC-conjugated anti-human IgG Fc (Biolegend; 409310; 1:300). The results of the FACS analysis are shown in Figure 8. P-selectin binding to monocytes from patients with SLC35C1 mutations was reduced compared to healthy controls, their mothers, and their fathers.

[0047] (Example 7) Analysis using EBV-transformed B cells Establishment and culture of EBV-transformed B cells EBV-transformed B cells were established from cells of an SLC35C1 mutation patient, the patient's father, the patient's mother, and a healthy control according to standard methods. EBV-transformed B cells were cultured in RPMI 1640 medium supplemented with 10% FBS and 1% penicillin / streptomycin. The cells were passaged daily.

[0048] Expression of sialyl Lewisx P-selectin expresses sialyl Lewisx (sLe X) recognizes sialyl Lewisx. We examined the cell surface expression of sialyl Lewisx using EBV-transformed B cells established from the patient, his mother, his father, and a healthy control. EBV-transformed B cells were stained with the antibody 2H5 (Tokyo Chemical Industry; A2849; 0.4 μg / ml), which recognizes sialyl Lewisx, and then incubated with FITC-conjugated anti-mouse IgM (Sigma Aldrich; F9259; 1:300). Then, the cells were analyzed by FACS. The results are shown in Figure 9. Expression of sialyl Lewisx was significantly reduced in EBV-transformed B cells from SLC35C1-mutant patients. Therefore, P-selectin-mediated monocyte rolling at inflammatory sites was defective, suggesting that infiltrates were not properly induced in SLC35C1-mutant patients who developed severe otitis media and hearing impairment.

[0049] (Example 8) Effect of fucose supplementation on patient cell lines in vitro Using patient-derived EBV-transformed B cells, we investigated whether adding fucose to the culture medium can restore cell surface fucose expression in patient-derived cells. EBV-transformed B cells were cultured in medium supplemented with 6 mM L-(-)-fucose, and the effect of fucose supplementation was confirmed by FACS analysis and MS analysis.

[0050] Before and 6 days after the addition of fucose, each cell was stained with CSLEX (5 μg / ml each), an antibody that recognizes AAL, LCA, and sialyl Lewisx, and analyzed by FACS. The results are shown in Figure 10. Before the addition of fucose, the expression of all fucosylated antigens in patient cells was significantly lower than in control cells. However, after the addition of fucose, the levels of AAL and LCA staining in patient cells returned to the levels in control cells. Meanwhile, the levels of AAL and LCA staining in control cells remained unchanged by the addition of fucose. Furthermore, the addition of fucose to the culture medium increased the expression of sialyl Lewisx in patient cells but not in control cells. These results indicate that the addition of fucose to the culture medium increased cell surface fucose and caused aggregation in cells derived from SLC35C1 mutant patients. This suggests the possibility of treating patients by ingestion of fucose and demonstrates that the therapeutic effects in patients can be confirmed using the method of the present invention.

[0051] Cells and medium were collected before and 6 days after the addition of fucose, and the glycan profiles were analyzed as in Example 4. The results are shown in Figure 11. Neutral and fucosylated N-glycans (N-16, N-21, and N-25) were observed in all EBV-transformed B cells and medium. After the addition of fucose, the N-glycan profile did not change in the control. However, in patient-derived B cells, biantennary N-glycans (N-27, N-49, and N-59) were specifically fucosylated, producing N-28, N-53, and N-61. On the other hand, triantennary and tetraantennary sialylated glycans were not fucosylated after the addition of fucose. MS analysis also confirmed that the amount of fucose added to glycans was restored by fucose intake (addition) to B cells established from the patient.

[0052] The above detailed description is merely illustrative of the objects and scope of the present invention and is not intended to limit the scope of the appended claims. Various modifications and substitutions to the described embodiments will be apparent to those skilled in the art from the teachings set forth herein, without departing from the scope of the appended claims.

[0053] This application is based on patent application No. 2023-083053 filed in Japan (filing date: May 19, 2023), the contents of which are incorporated in their entirety herein.

[0054] According to the present invention, whether or not a subject has a loss-of-function mutation in the SLC35C1 gene can be confirmed by a simple method using the subject's peripheral blood. The present invention is useful for detecting SLC35C1 mutation-associated diseases.

Claims

1. A method for determining whether or not a subject has or is suspected to have a loss-of-function mutation in the SLC35C1 gene that encodes a GDP-fucose transporter, the method comprising the step of performing a hemagglutination reaction using blood from the subject with a lectin or antibody that recognizes a glycan antigen of red blood cells or white blood cells that contains fucose.

2. The lectin or antibody that recognizes the sugar chain containing fucose is Ulex Europaeus Agglutinin I (UEA-I), Aleuria Aurantia Lectin (AAL), BC2LCN (AiLecS1) lectin, Aspergillus fumigatus lectin (AFL), Pholiota squarrosa Lectin (PhoSL), E-Selectin, P-Selectin, L-Selectin, DC-SIGN, Lens Culinaris Agglutinin (LCA), Aspergillus oryzae lectin (AOL), Lotus Tetragonolobus Lectin (LTA), European eel lectin (Anguilla anguilla var. ...

2. The method according to claim 1, wherein the lectin is selected from the group consisting of PA-IIL and RS-Fuc lectin.

3. The method of claim 1, wherein the lectin or antibody that recognizes the glycan containing fucose is a lectin or antibody that recognizes a glycan containing core fucose.

4. The method of claim 3, wherein the lectin or antibody that recognizes the glycan containing core fucose is a lectin selected from the group consisting of LCA, AOL, AAL, AFL and PhoSL.

5. The method of claim 2, characterized in that the lectin or antibody that recognizes the fucose-containing glycan is a combination of a lectin or antibody that recognizes a core fucose-containing glycan and a lectin or antibody that recognizes a glycan that contains fucose at the non-reducing end of the glycan.

6. The method of claim 5, wherein the combination is a combination of a lectin that recognizes a glycan containing at least one core fucose selected from the group consisting of AAL, AFL, PhoSL, LCA, and AOL, and a lectin that recognizes a glycan containing at least one terminal fucose selected from AAL, AFL, E-selectin, P-selectin, L-selectin, UEA-I, BC2LCN (AiLecS1), PA-IIL, and RS-Fuc.

7. The method of claim 6, wherein the combination is any one of AAL, AFL, PhoSL, LCA, and AOL and UAE-I.

8. The method of claim 1, wherein the antibody that recognizes the glycan containing red fucose is at least one antibody selected from the group consisting of anti-H antibody, anti-sialyl Lewis X antibody, anti-sialyl Lewis A antibody, anti-Lewis X antibody, anti-Lewis Y antibody, anti-Lewis A antibody, anti-Lewis B antibody, and anti-core fucose antibody.

9. The method of any one of claims 1 to 8, wherein the loss-of-function mutation is a nonsense mutation or a missense mutation.

10. The method of any one of claims 1 to 8, wherein the blood derived from the subject is peripheral blood.

11. The method according to any one of claims 1 to 8, further comprising the following step: determining that the subject has a loss-of-function mutation in the SLC35C1 gene when no hemagglutination reaction is observed in the subject's blood or when the reaction is insufficient compared to a control.

12. The method of claim 11, further comprising the step of determining that a subject having a loss-of-function mutation in the SLC35C1 gene is a subject in need of treatment or observation.

13. A method for determining whether or not a subject has or is suspected of having a loss-of-function mutation in the SLC35C1 gene encoding a GDP-fucose transporter, comprising the step of performing an ELISA assay using blood from the subject with an antibody that recognizes a glycan antigen of blood cells (red blood cells or white blood cells) that contains fucose.

14. The method according to claim 13, wherein the antibody that recognizes the sugar chain containing fucose is at least one antibody selected from the group consisting of anti-H antibody, anti-sialyl Lewis X antibody, anti-sialyl Lewis A antibody, anti-Lewis X antibody, anti-Lewis Y antibody, anti-Lewis A antibody, anti-Lewis B antibody, and anti-core fucose antibody.

Citation Information

Patent Citations

  • Means and methods for protein glycosylation profiling

    JP2021519443A